Marina Baretti
About
Marina Baretti is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Marina Baretti has authored 50 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 12 papers in Surgery and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marina Baretti's work include Cancer Immunotherapy and Biomarkers (14 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Marina Baretti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Marina Baretti collaborates with scholars based in United States, Italy and United Kingdom. Marina Baretti's co-authors include Dung T. Le, Nilofer S. Azad, Armando Santoro, Jeffrey M. Gerold, Johannes G. Reiter, Martin A. Nowak, Kenneth W. Kinzler, Christine A. Iacobuzio–Donahue, Adil Daud and Alvin P. Makohon-Moore and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.
In The Last Decade
Marina Baretti
43 papers receiving 959 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Marina Baretti United States | 13 | 531 | 367 | 333 | 293 | 211 | 50 | 969 | ||
| Chit Chow Hong Kong | 21 | 646 1.2× | 534 1.5× | 396 1.2× | 568 1.9× | 184 0.9× | 53 | 1.4k | ||
| Muhammad A. Khattak Australia | 19 | 848 1.6× | 389 1.1× | 505 1.5× | 276 0.9× | 95 0.5× | 44 | 1.2k | ||
| Yuezong Bai China | 15 | 629 1.2× | 248 0.7× | 268 0.8× | 402 1.4× | 158 0.7× | 60 | 987 | ||
| Tsui‐Lien Mao Taiwan | 14 | 321 0.6× | 500 1.4× | 188 0.6× | 161 0.5× | 146 0.7× | 24 | 1.0k | ||
| Chongkai Wang United States | 18 | 733 1.4× | 262 0.7× | 234 0.7× | 178 0.6× | 338 1.6× | 46 | 1.1k | ||
| Chin‐Tung Chen United States | 12 | 574 1.1× | 387 1.1× | 152 0.5× | 259 0.9× | 184 0.9× | 24 | 988 | ||
| Consalvo Petti Italy | 12 | 614 1.2× | 432 1.2× | 344 1.0× | 137 0.5× | 245 1.2× | 21 | 988 | ||
| J.P. Delord France | 18 | 706 1.3× | 253 0.7× | 162 0.5× | 276 0.9× | 86 0.4× | 48 | 981 | ||
| Jeroen Dekervel Belgium | 18 | 617 1.2× | 316 0.9× | 230 0.7× | 165 0.6× | 165 0.8× | 69 | 1.1k | ||
| Zacharenia Saridaki Greece | 17 | 1.1k 2.1× | 284 0.8× | 349 1.0× | 370 1.3× | 463 2.2× | 39 | 1.3k |
Countries citing papers authored by Marina Baretti
Since
Specialization
Citations
This map shows the geographic impact of Marina Baretti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Baretti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Baretti more than expected).
Fields of papers citing papers by Marina Baretti
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marina Baretti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Baretti. The network helps show where Marina Baretti may publish in the future.
Co-authorship network of co-authors of Marina Baretti
This figure shows the co-authorship network connecting the top 25 collaborators of Marina Baretti. A scholar is included among the top collaborators of Marina Baretti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Baretti. Marina Baretti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kim, Amy K., Mark Yarchoan, Marina Baretti, et al.. (2025). Safety and efficacy of combining PD-L1 and CTLA-4 blockade with transarterial chemoembolization in intermediate-stage hepatocellular carcinoma: A phase II study.. Journal of Clinical Oncology. 43(4_suppl). 609–609.
2.
Kelley, Robin Kate, James M. Cleary, Vaibhav Sahai, et al.. (2024). A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4197–TPS4197.
3.
D’Alessio, Antonio, Bernardo Stefanini, Claudia Angela Maria Fulgenzi, et al.. (2024). Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.. Journal of Clinical Oncology. 42(3_suppl). 506–506.
4.
Mohseni, Alireza, Azarakhsh Baghdadi, Seyedeh Panid Madani, et al.. (2024). Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters. Abdominal Radiology. 49(8). 2595–2605.
5.
Baretti, Marina, Adrian Murphy, Marianna Zahurak, et al.. (2023). A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clinical Epigenetics. 15(1). 74–74.
6.
Alden, Stephanie, Chester Kao, Daniel Shu, et al.. (2023). Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer Research Communications. 3(7). 1312–1317.
7.
Baretti, Marina, Yingjun Ding, Rose Parkinson, et al.. (2023). A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology. 41(16_suppl). e16217–e16217.
8.
Alden, Stephanie, Chester Kao, Daniel Shu, et al.. (2023). Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.. Journal of Clinical Oncology. 41(16_suppl). 4091–4091.
9.
Chen, Krista Y., Aleksandra Popović, David Hsiehchen, et al.. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers. 14(21). 5347–5347.
10.
Baretti, Marina, Amy K. Kim, & Robert A. Anders. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell. 40(3). 252–254.
11.
Baretti, Marina, Enusha Karunasena, Marianna Zahurak, et al.. (2021). A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science. 14(3). 954–963.
12.
Baretti, Marina & Nilofer S. Azad. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal. 25(4). 287–295.
13.
Reiter, Johannes G., Marina Baretti, Jeffrey M. Gerold, et al.. (2019). An analysis of genetic heterogeneity in untreated cancers. Nature reviews. Cancer. 19(11). 639–650.
14.
Baretti, Marina, Lorenza Rimassa, Nicola Personeni, et al.. (2018). Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer. 17(3). e489–e498.
15.
Baretti, Marina & Dung T. Le. (2018). DNA mismatch repair in cancer. Pharmacology & Therapeutics. 189. 45–62.
16.
Personeni, Nicola, Marina Baretti, Silvia Bozzarelli, et al.. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer. 20(3). 428–437.
17.
Metro, Giulio, Biagio Ricciuti, Rita Chiari, et al.. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer. 95. 82–87.
18.
Bozzarelli, Silvia, Lorenza Rimassa, Laura Giordano, et al.. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology. 26. vi150–vi150.
19.
Ghidini, Michele, Nicola Personeni, Silvia Bozzarelli, et al.. (2015). KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine. 5(2). 256–264.
20.
Sefrioui, David, Nasrin Sarafan‐Vasseur, Ludivine Beaussire, et al.. (2015). Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Digestive and Liver Disease. 47(10). 884–890.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chit Chow Breakdown of academic impact, for papers by Muhammad A. Khattak Breakdown of academic impact, for papers by Yuezong Bai Breakdown of academic impact, for papers by Tsui‐Lien Mao Breakdown of academic impact, for papers by Chongkai Wang Breakdown of academic impact, for papers by Chin‐Tung Chen Breakdown of academic impact, for papers by Consalvo Petti Breakdown of academic impact, for papers by J.P. Delord Breakdown of academic impact, for papers by Jeroen Dekervel Breakdown of academic impact, for papers by Zacharenia Saridaki